Genmab A/S (GMAB) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed Genmab A/S (GMAB) over the past year, gaining 68.4% versus a gain of 12.3%. Over five years, JAZZ leads with a +64.3% price change compared with -17.5% for GMAB. Genmab A/S is the larger company by market cap ($21.69 billion vs $14.06 billion), about 1.5 times the size.
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.4x vs 23.1x for Genmab A/S). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus -8.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | JAZZ |
|---|---|---|
| Share price | $35.27 | $216.56 |
| Market cap | $21.69B | $14.06B |
| 1-day change | -3.77% | -6.33% |
| YTD return | +18.99% | +35.99% |
| 1-year return | +12.29% | +68.36% |
| 5-year return | -17.51% | +64.31% |
| P/E ratio (TTM) | 27.77 | 14.84 |
| Forward P/E | 23.13 | 8.36 |
| EPS (TTM) | $1.27 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $4.27B |
| Revenue growth (YoY) | +19.19% | +4.88% |
| Net income (latest FY) | $963.00M | $-356.15M |
| Gross margin | 93.60% | — |
| Operating margin | 28.63% | -10.08% |
| Net margin | 25.89% | -8.35% |
| 52-week high | $40.17 | $266.38 |
| 52-week low | $23.62 | $128.80 |
| Distance from 52-week high | -12.20% | -18.70% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +22.54% | +35.99% |
| Average volume | 2.80M | 850.55K |
| Shares outstanding | 614.90M | 64.91M |
| Employees | 3,119 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed GMAB by 56.1 percentage points over the past year.
- Genmab A/S trades at a higher earnings multiple (27.8x vs 14.8x trailing P/E).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus -8.3 cents for Jazz Pharmaceuticals.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs +4.88%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
GMAB vs JAZZ FAQ
Which is bigger, Genmab A/S or Jazz Pharmaceuticals?
Genmab A/S (GMAB) is larger, with a market capitalization of $21.69B compared with $14.06B for Jazz Pharmaceuticals (JAZZ).
Which stock has performed better over the past year, GMAB or JAZZ?
JAZZ returned +68.36% over the past 12 months, compared with +12.29% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or JAZZ?
JAZZ has the lower trailing P/E at 14.8, versus 27.8 for GMAB. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Genmab A/S and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.